New England Journal of Medicine December 31, 2020

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Fernando P. Polack, Stephen J. Thomas, Nicholas Kitchin, et al.

Bottom Line

In a pivotal multinational trial, a two-dose regimen of the BNT162b2 mRNA vaccine demonstrated 95% efficacy in preventing COVID-19 illness, with a favorable short-term safety profile.

Key Findings

1. Atotalof43, 548participantsunderwentrandomization, with43, 448receivingatleastoneinjection(21, 720BNT162b2;21, 728placebo)[1.2].

2. There were 8 cases of COVID-19 with onset at least 7 days after the second dose in the BNT162b2 group compared to 162 cases in the placebo group.

3. The vaccine demonstrated 95.0% efficacy (95% credible interval, 90.3 to 97.6) in preventing laboratory-confirmed COVID-19.

4. Efficacy remained robust (generally 90% to 100%) across diverse subgroups defined by age, sex, race, ethnicity, and baseline body-mass index.

5. Among 10 cases of severe COVID-19 observed after the first dose, 9 occurred in the placebo arm and 1 in the BNT162b2 arm.

6. The safety profile was characterized by mild-to-moderate, transient injection-site pain, fatigue, and headache, with the incidence of serious adverse events being low and similar between the vaccine and placebo groups.

Study Design

Design

Phase 3 RCT

Observer-Blind

Sample

43,548

Patients

Duration

2 mo

Median

Setting

Multinational

Population Healthy adults and adolescents ≥16 years of age

Intervention BNT162b2 vaccine (30 μg), two doses administered 21 days apart

Comparator Saline placebo, two doses administered 21 days apart

Outcome Efficacy against laboratory-confirmed COVID-19 and safety

Study Limitations

• Mediansafetyfollow-upwasonly2monthsatthetimeofpublication, precludingtheinitialassessmentofrarelong-termadverseeventsorthelong-termdurabilityofimmuneprotection[1.2].

• The initial study excluded key populations such as children under 16, pregnant individuals, and severely immunocompromised patients.

• The trial was not originally designed to detect differences in asymptomatic infection rates or viral transmission dynamics.

• Data were collected before the widespread emergence of subsequent SARS-CoV-2 variants of concern (e.g., Delta, Omicron), limiting insight into variant-specific breakthrough efficacy.

Clinical Significance

This landmark trial provided the definitive clinical evidence required for the FDA Emergency Use Authorization (EUA) of the first COVID-19 vaccine. By demonstrating 95% efficacy and a tolerable safety profile, the findings mobilized global mass vaccination campaigns that successfully prevented millions of severe infections and deaths worldwide, fundamentally altering the trajectory of the pandemic.

Historical Context

Conducted amidst the devastating first year of the COVID-19 pandemic, this study represents a watershed moment in medical history. Supported by Operation Warp Speed, it successfully compressed a standard multi-year vaccine development timeline into less than a year. Furthermore, it marked the first successful large-scale human validation of mRNA vaccine technology—a triumph decades in the making that subsequently earned the Nobel Prize in Physiology or Medicine.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does the BNT162b2 mRNA vaccine utilize host cellular machinery to generate immunity, and what specific role does the lipid nanoparticle play in this process?

Key Response

This tests foundational immunology and pharmacology. The mRNA must enter the cytoplasm to be translated into the SARS-CoV-2 spike protein, which is then presented on MHC molecules. The lipid nanoparticle is crucial because it protects the fragile mRNA from extracellular ribonucleases and facilitates endocytosis into host cells.

Resident

The trial demonstrated 95% efficacy but excluded individuals with a history of severe adverse reactions to vaccines and those on immunosuppressive therapy. How do you apply these findings when counseling a patient with a controlled autoimmune disease on biologic therapy?

Key Response

Focuses on clinical application. Residents must recognize that while the trial excluded these patients, the mechanism of mRNA vaccines (non-live) is generally safe for immunocompromised patients, though their robust efficacy might be blunted. It highlights the need to balance trial exclusion criteria against real-world risk-benefit profiles.

Fellow

The primary trial endpoints focused on symptomatic COVID-19 illness rather than asymptomatic infection. As a subspecialty fellow, how does this distinction impact our understanding of the vaccine's ability to achieve sterilizing immunity and halt viral transmission?

Key Response

Encourages nuanced interpretation of trial endpoints. The BNT162b2 trial was powered for symptomatic disease, meaning asymptomatic shedding could still occur. Fellows must understand the difference between disease-modifying immunity and sterilizing immunity, which heavily influences transmission dynamics and infection control policies.

Attending

Given the unprecedented speed of the BNT162b2 trial and subsequent Emergency Use Authorization, how do you navigate the challenge of addressing vaccine hesitancy fueled by concerns over long-term safety, using the trial's safety data and the biological plausibility of mRNA degradation?

Key Response

Explores attending-level communication and leadership. Attendings must synthesize the trial's robust short-term safety data with an understanding of mRNA pharmacokinetics (rapid degradation) to confidently reassure patients and colleagues, translating high-level trial data into digestible, reassuring clinical practice.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The study utilized a case-driven design with an interim analysis. What are the statistical implications of using Bayesian boundaries for early stopping for efficacy in this context, and how does this impact the precision of the point estimate for vaccine efficacy?

Key Response

Critiques statistical methodology. Using early stopping rules in a case-driven design can lead to an overestimation of the treatment effect and wider confidence intervals around the final efficacy estimate, requiring researchers to carefully adjust alpha spending and consider the impact on subsequent long-term follow-up.

Journal Editor

From an editorial perspective, the decision to unblind the placebo group and offer them the vaccine post-EUA creates a significant methodological challenge. How does this crossover impact the trial's original objective to assess long-term safety and durability of protection?

Key Response

Highlights critical appraisal of trial integrity. Unblinding and crossing over the placebo arm effectively destroys the concurrent control group, making it extremely difficult to differentiate long-term adverse events or waning immunity from background population rates, a major trade-off between ethics and methodological rigor.

Guideline Committee

How does the Level 1 evidence of 95% efficacy from this trial inform the Advisory Committee on Immunization Practices recommendations for phased vaccine rollout, specifically regarding the prioritization of healthcare personnel and vulnerable populations?

Key Response

Connects trial data to guideline formulation. Guideline committees had to utilize this high-quality efficacy data alongside epidemiological data on morbidity and mortality to formulate the ACIP Phase 1a recommendations, balancing the immediate need to preserve healthcare capacity and protect the most vulnerable despite the lack of long-term durability data.

Clinical Landscape

Noteworthy Related Trials

2020

COVE Trial

n = 30,420 · NEJM

Tested

mRNA-1273 (Moderna) vaccine 100 mcg

Population

Adults at risk for SARS-CoV-2 infection

Comparator

Placebo

Endpoint

Prevention of symptomatic Covid-19

Key result: The vaccine demonstrated 94.1 percent efficacy at preventing Covid-19 illness.

2020

ChAdOx1 nCoV-19 Vaccine Efficacy Trial

n = 23,848 · Lancet

Tested

ChAdOx1 nCoV-19 (AZD1222) vaccine

Population

Adults 18 years and older

Comparator

MenACWY vaccine or saline placebo

Endpoint

Symptomatic Covid-19

Key result: The overall vaccine efficacy was 70.4 percent in preventing symptomatic Covid-19.

2021

ENSEMBLE Trial

n = 44,325 · NEJM

Tested

Single-dose Ad26.COV2.S vaccine

Population

Adults 18 years and older

Comparator

Placebo

Endpoint

Moderate to severe-critical Covid-19

Key result: A single dose provided 66.9 percent efficacy against symptomatic Covid-19 and high protection against severe disease.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis